The global Progressive Pulmonary Fibrosis (PPF) Treatment Market is set to achieve a valuation of USD 3.72 million in 2023, ...

Identifying the underlying causes of prolonged lung inflammation associated with radiographic abnormalities could be key understanding long COVID and other lung conditions, researchers say.

including idiopathic pulmonary fibrosis (IPF). “These compelling results support advancing the development of nintedanib DPI for patients living with IPF, a chronic and progressive fibrotic lung ...

Delayed IPF diagnosis often results in significant lung function impairment, impacting patient outcomes and increasing hospitalization rates. Antifibrotic therapies, nintedanib and pirfenidone ...

Columnist Sam Kirton is doing a service for him and his family's future generations by sharing his research on the family ...

The effort by the Center for Regenerative Medicine of Boston University, Boston Medical Center, and GSK aims to find new ...

Maria L. Padilla, MD, Icahn School of Medicine at Mount Sinai, previews that experts will discuss critical management strategies for interstitial lung disease and idiopathic pulmonary fibrosis, ...

Under the terms of the agreement, Surrozen will provide antibody discovery services for a period of up to two years. TCGFB will own all TGF-β product related intellectual property. In exchange for ...

CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled therapies for the treatment of life-threatening ...

The asset at play is fipaxalparant, a candidate designed to block the lysophosphatidic acid receptor 1 (LPAR1). Amgen tested ...

Research collaboration to leverage Surrozen's antibody research capabilities and expertise to discover a potential first in class <a target=_blank ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...